About Exonics
Exonics is a company based in Boston (United States) founded in 2016 was acquired by Vertex Pharmaceuticals in June 2019. Exonics has raised $67.04 million across 3 funding rounds from investors including Vertex Pharmaceuticals, The Column Group and CureDuchenne. Exonics operates in a competitive market with competitors including Alnylam, Denali Therapeutics, Ultragenyx, Beam Therapeutics and Poseida Therapeutics, among others.
- Headquarter Boston, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$67.04 M (USD)
in 3 rounds
-
Latest Funding Round
$22.04 M (USD), Series A
Nov 17, 2018
-
Investors
Vertex Pharmaceuticals
& 2 more
-
Employee Count
Not available
-
Acquired by
Vertex Pharmaceuticals
(Jun 06, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Exonics
Exonics has successfully raised a total of $67.04M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $22.04 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Exonics
Exonics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Vertex Pharmaceuticals, The Column Group and CureDuchenne.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments in US life science startups are focused on.
|
Locked | Locked | Locked | |
|
Nonprofit organization funding research and providing support for Duchenne patients.
|
Locked | Locked | Locked | |
|
Developer of drugs for the treatment of multiple disorders
|
Locked | Locked | Locked |
Investor details for Exonics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Exonics
Investment portfolio details for Exonics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Exonics
Detailed financials for Exonics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Exonics Comparisons
Peer comparison for Exonics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Exonics
Exonics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Denali Therapeutics, Ultragenyx, Beam Therapeutics and Poseida Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of gene therapy using CRISPR base editing to treat diseases
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
Detailed competitors of Exonics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Exonics
Complete news archive for Exonics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exonics
Exonics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Exonics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Exonics is a funded company, having raised a total of $67.04M across 3 funding rounds to date.
Exonics was founded in 2016 as a biotech spin-out from the University of Texas Southwestern Medical Center, focusing on gene editing for rare diseases. CRISPRCas-9 technologies are utilized to target Duchenne Muscular Dystrophy mutations, with AAV delivery tested in mouse models showing dystrophin restoration. Seed funding of 5 million was secured in 2017 from CureDuchenne Ventures. Operations are based in Boston, United States.
Exonics's top competitors include Juno Therapeutics, Alnylam and BioMarin Pharmaceutical.
Exonics has 3 investors. Key investors include Vertex Pharmaceuticals, The Column Group, and CureDuchenne.